Emodol0.5%

Emodol is a nonsteroidal anti-inflammatory drug (NSAID) approved for the short-term management of pain. It is intended for brief courses of therapy only and is not indicated for minor or chronic pain conditions.

Established (FDA-approved) uses

• Short-term management of moderately severe acute pain (oral and injectable forms) requiring analgesia at the opioid level, usually used as continuation therapy after initial treatment with injectable Emodol, or as an alternative to opioids. Total combined duration (oral plus injectable) must not exceed 5 days.
• Ophthalmic solution: temporary relief of ocular itching due to seasonal allergic conjunctivitis; treatment of postoperative inflammation following cataract surgery; and reduction of ocular pain, burning/stinging, and photophobia after corneal refractive surgery.

Not indicated for

• Minor pain, chronic pain conditions, or long-term use.
• Use as a first-line or sole analgesic in pediatric patients (see Pediatric Uses).

Emodol is not an antibiotic and has no role in treating infections.

Each formulation of Ketorolac Tromethamine marketed in Bangladesh typically contains:

• Tablet: Ketorolac Tromethamine INN 10 mg per tablet.
• Injection (IM/IV): Ketorolac Tromethamine equivalent to 30 mg/mL or 60 mg/2 mL ketorolac.
• Ophthalmic solution: Ketorolac Tromethamine equivalent to 0.5% w/v (5 mg/mL) ketorolac.

Excipients vary by manufacturer; refer to the specific product's package insert for the complete excipient list.

Emodol is a potent, non-selective nonsteroidal anti-inflammatory drug (NSAID) belonging to the pyrrolizine-carboxylic acid (heterocyclic acetic acid) group. It works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin production and providing analgesic and anti-inflammatory effects without opioid-related respiratory depression or dependence.

Emodol is available as oral tablets, intramuscular/intravenous injection, and ophthalmic solution. Because of its potent gastrointestinal, renal, and bleeding-related risks, its systemic (oral/injectable) use is strictly limited to short-term (5 days or less) management of moderate to severe acute pain.

Emodol belongs to the class of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), specifically the pyrrolizine carboxylic acid derivatives. It is classified as a non-selective, potent NSAID analgesic. The ophthalmic formulation is classified separately as an ophthalmic NSAID (topical anti-inflammatory/analgesic for the eye).

Ketorolac Tromethamine is a non-selective, reversible inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes. By blocking these enzymes, it reduces the peripheral synthesis of prostaglandins and thromboxanes, the mediators responsible for pain, inflammation, and fever.

Unlike opioids, Ketorolac Tromethamine has no effect on opioid receptors and does not cause respiratory depression, sedation dependence, or tolerance, but its potent COX inhibition accounts for its notable gastrointestinal, renal, and bleeding-related risk profile (see Precautions and Warnings).

Emodol tablets should be swallowed whole with water and may be taken with food or milk to reduce stomach upset, though this may slightly delay onset. Injectable Emodol should be given as a slow, deep intramuscular injection or as an intravenous bolus given over no less than 15 seconds; it should not be mixed in the same syringe with other drugs. Emodol ophthalmic solution should be instilled directly into the conjunctival sac; contact lenses should be removed before instillation and may be reinserted after 15 minutes. See Dosage and Administration for complete dosing details.

Emodol has several clinically significant drug interactions:

• Aspirin or other NSAIDs: Concurrent use is contraindicated — increases the risk of serious gastrointestinal ulceration and bleeding without added therapeutic benefit.
• Anticoagulants (e.g., warfarin, heparin) and antiplatelet agents: Increased risk of serious bleeding due to additive effects on platelet function and coagulation; avoid combination or monitor very closely.
• Probenecid: Contraindicated — significantly reduces Emodol clearance, raising plasma levels and toxicity risk.
• Pentoxifylline: Contraindicated — increases risk of bleeding.
• ACE inhibitors, ARBs, and diuretics: Emodol may reduce their antihypertensive/natriuretic effect and, particularly in volume-depleted or renally impaired patients, increases the risk of acute renal failure ("triple whammy" effect with diuretic plus ACE inhibitor/ARB).
• Lithium: Emodol can reduce renal clearance of lithium, raising plasma lithium levels and toxicity risk; monitor lithium levels if co-administered.
• Methotrexate: Emodol may reduce methotrexate clearance, increasing risk of methotrexate toxicity.
• Corticosteroids and SSRIs: Additive increase in risk of gastrointestinal ulceration/bleeding when combined with Emodol.

Always inform the prescriber of all other medicines being taken before starting Emodol.

Side effects associated with Emodol range from common and mild to rare but serious:

Common

• Gastrointestinal: dyspepsia, nausea, abdominal pain, diarrhea.
• Central nervous system: headache, dizziness, drowsiness.
• Edema and mild elevation of liver enzymes.
• Local injection-site pain (injectable form); transient stinging/burning (ophthalmic form).

Serious (less common but important)

• Gastrointestinal ulceration, bleeding, or perforation (can occur without warning symptoms).
• Acute renal failure, interstitial nephritis, or renal papillary necrosis.
• Increased bleeding tendency, prolonged bleeding time, purpura.
• Hypersensitivity reactions including rash, urticaria, bronchospasm, and rarely anaphylaxis, Stevens-Johnson syndrome, or toxic epidermal necrolysis.
• Hepatic dysfunction or, rarely, hepatic failure.
• Cardiovascular thrombotic events (myocardial infarction, stroke), especially with longer use.
• Aseptic meningitis (rare).

Patients should seek prompt medical attention for signs of GI bleeding (black or bloody stools, vomiting blood), unexplained bruising/bleeding, severe skin reactions, or reduced urine output.

Emodol should generally be avoided during pregnancy. Use during the first and second trimesters should be limited to situations where the potential benefit clearly justifies the potential risk to the fetus, at the lowest effective dose for the shortest possible duration, and only under close physician supervision, because NSAIDs used around 20 weeks gestation or later have been associated with fetal renal dysfunction that can lead to oligohydramnios and, in some cases, neonatal renal impairment.

Emodol must be avoided at or after 30 weeks of gestation due to the risk of premature closure of the fetal ductus arteriosus, and it is contraindicated during labor and delivery because of effects on uterine contractions and increased risk of bleeding in the mother and infant.

Emodol is contraindicated in nursing mothers. Breastfeeding should not be resumed until a physician confirms it is safe to do so.

Emodol carries several serious risks that require caution:

• Gastrointestinal risk: Can cause serious GI adverse events including bleeding, ulceration, and perforation of the stomach or intestines at any time during use, with or without warning symptoms; this risk is higher than with many other NSAIDs and increases with age, history of peptic ulcer disease, and duration of use.
• Cardiovascular risk: NSAIDs, including Emodol, may increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal; this risk may increase with duration of use.
• Renal risk: May cause renal papillary necrosis and other renal injury, particularly in patients with pre-existing renal impairment, heart failure, liver dysfunction, or volume depletion; Emodol is contraindicated in advanced renal impairment.
• Bleeding risk: Inhibits platelet aggregation and can prolong bleeding time; use with extreme caution in patients with bleeding disorders or those on anticoagulants.
• Strict duration limit: Combined use of all Emodol formulations (oral and injectable) must never exceed 5 days due to increasing risk of the above complications with prolonged use.
• Hypersensitivity, hepatotoxicity, fluid retention, and hypertension can occur; use caution in patients with heart failure or hepatic impairment, and monitor accordingly.
• Use the lowest effective dose for the shortest duration consistent with the treatment goal.

Symptoms of Emodol overdose may include severe abdominal pain, nausea, vomiting, gastrointestinal bleeding, drowsiness, dizziness, hyperventilation, and in severe cases, seizures or acute kidney injury.

If an overdose of Emodol is suspected, seek immediate medical attention or contact emergency services/a poison control center right away. There is no specific antidote; treatment is supportive and symptomatic (e.g., gastric decontamination if given promptly after ingestion, and management of GI bleeding, renal function, and fluid/electrolyte status as needed). Hemodialysis does not effectively remove significant amounts of the drug. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), protected from light and moisture. Do not freeze injectable solutions. Keep out of reach of children.

Renal impairment: Emodol is contraindicated in advanced renal impairment or in patients at risk of renal failure due to volume depletion. A reduced dose is required in mild-to-moderate renal impairment (see Dosage and Administration).

Hepatic impairment: Use with caution; Emodol has not been well studied in significant hepatic disease and should generally be avoided in such patients.

Elderly: Older adults are more sensitive to the gastrointestinal, renal, and cardiovascular effects of Emodol and require reduced doses and close monitoring (see Dosage and Administration).

Pediatric patients: See Pediatric Uses.

Pregnant and breastfeeding women: See Pregnancy and Lactation.

Treatment with Emodol (oral and/or injectable, combined) must not exceed a total of 5 days. Emodol is not intended for chronic pain management or long-term use; if pain persists beyond this period, the patient should be reassessed and transitioned to another appropriate analgesic under medical supervision. The ophthalmic solution's duration of use should follow the specific product's approved course (e.g., up to 2 weeks post-cataract surgery), as directed by the prescribing physician.

Nonsteroidal Anti-Inflammatory Drug (NSAID); pyrrolizine carboxylic acid derivative; non-selective COX-1/COX-2 inhibitor; ophthalmic NSAID (eye drop formulation).

Ketorolac Tromethamine works by non-selectively and reversibly inhibiting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), the enzymes responsible for converting arachidonic acid into prostaglandins and thromboxanes. By reducing prostaglandin synthesis at the site of tissue injury and inflammation, Ketorolac Tromethamine produces potent analgesic and anti-inflammatory effects. See Pharmacology for full pharmacokinetic details.

Category C (before 30 weeks gestation); Category D (at or after 30 weeks gestation, or when used at term).

The safety and efficacy of Emodol have not been established in pediatric patients, and current labeling states that oral and injectable Emodol are not indicated for use in pediatric patients. Emodol should not be used in children and adolescents outside of a specialist setting where a physician judges the potential benefit clearly outweighs the risk, with close monitoring. Emodol ophthalmic solution use in children should also only be under direct physician guidance, as pediatric ophthalmic safety data are limited.